Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update

Cue Biopharma, Inc. (NASDAQ:CUE) was the target of a large decline in short interest in April. As of April 30th, there was short interest totaling 288,887 shares, a decline of 96.2% from the April 15th total of 7,541,901 shares. Based on an average daily volume of 533,660 shares, the days-to-cover ratio is presently 0.5 days. Approximately 9.1% of the company’s stock are sold short.

Cue Biopharma Trading Down 8.0%

Shares of NASDAQ CUE traded down $2.49 during trading on Tuesday, reaching $28.83. 91,603 shares of the company traded hands, compared to its average volume of 524,829. The stock has a market cap of $93.41 million, a P/E ratio of -2.99 and a beta of 2.37. The firm’s fifty day simple moving average is $245.26 and its 200 day simple moving average is $350.73. Cue Biopharma has a 12-month low of $4.97 and a 12-month high of $41.42.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CUE shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Cue Biopharma in a research report on Friday, March 27th. Wall Street Zen upgraded shares of Cue Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Trading of Cue Biopharma

Institutional investors have recently bought and sold shares of the business. GC Wealth Management RIA LLC boosted its holdings in Cue Biopharma by 35.0% in the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock worth $1,415,000 after buying an additional 1,200,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc raised its holdings in shares of Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after acquiring an additional 407,568 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after acquiring an additional 73,000 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Cue Biopharma in the third quarter valued at approximately $62,000. Finally, Stifel Financial Corp increased its position in shares of Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares in the last quarter. 35.04% of the stock is owned by institutional investors and hedge funds.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.